CLDX

+ Watchlist + Portfolio

Celldex Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $41.70
52-Week Range: $20.37 – $45.14
Market Cap: $3.14B
P/E (TTM): —
EPS (TTM): -4.35
Dividend Yield: —

Advanced Metrics

Price/Book: 4.39
PEG Ratio: —
Return on Equity: -43.88%
Return on Assets: -27.62%
Gross Margin: 0.00%
Operating Margin: -366468.20%
Profit Margin: 0.00%
Current Ratio: 11.82
Debt/Equity: 0.01
Total Debt: $4.90M
Free Cash Flow: $-133.08M
Revenue Growth: -97.00%
Earnings Growth: —
Enterprise Value: $2.56B

CLDX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.36M	$6.88M	$7.02M	$1.54M
Research & Development	$82.26M	$118.01M	$163.55M	$245.07M
Selling, General & Admin	$27.20M	$30.91M	$38.55M	$43.84M
Operating Expenses	$109.45M	$148.93M	$202.10M	$288.91M
Operating Income	-$107.10M	-$142.04M	-$195.08M	-$287.37M
EBITDA	-$104.20M	-$139.03M	-$191.90M	-$283.99M
Pretax Income	-$112.33M	-$141.43M	-$157.86M	-$258.76M
Income Tax	$0.00	$0.00	—	—
Net Income	-$112.33M	-$141.43M	-$157.86M	-$258.76M
Diluted EPS	-2.40	-2.92	-2.45	-3.90
Diluted Shares	46.89M	48.45M	64.39M	66.42M

CLDX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$29.43M	$34.81M	$28.36M	$28.87M
Receivables	$347.00K	$2.63M	$700.00K	$2.02M
Current Assets	$317.69M	$431.69M	$747.16M	$534.66M
Total Assets	$352.74M	$465.63M	$792.34M	$582.98M
Current Liabilities	$18.61M	$31.13M	$39.50M	$50.99M
Total Debt	$4.03M	$2.54M	$3.81M	$2.34M
Total Liabilities	$26.53M	$36.46M	$45.34M	$55.82M
Retained Earnings	-$1.26B	-$1.40B	-$1.56B	-$1.81B
Shareholders' Equity	$326.20M	$429.17M	$747.00M	$527.16M
Working Capital	$299.08M	$400.57M	$707.66M	$483.67M

CLDX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$103.73M	-$107.29M	-$157.78M	-$210.94M
Capital Expenditure	-$1.83M	-$1.82M	-$1.92M	-$2.71M
Free Cash Flow	-$105.56M	-$109.11M	-$159.70M	-$213.66M
Depreciation & Amortisation	$2.90M	$3.01M	$3.18M	$3.38M
Stock-Based Compensation	$15.61M	$23.89M	$34.24M	$36.22M
Investing Cash Flow	$89.94M	-$105.78M	-$290.13M	$209.07M
Financing Cash Flow	$4.08M	$218.46M	$441.45M	$2.39M
Net Change in Cash	-$9.71M	$5.38M	-$6.46M	$515.00K

CLDX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$695.00K	$730.00K	$0.00	$121.00K	$15.00K
Research & Development	$52.61M	$54.20M	$62.93M	$75.33M	$73.00M
Selling, General & Admin	$10.82M	$10.39M	$10.69M	$11.94M	$11.45M
Operating Expenses	$63.43M	$64.59M	$73.62M	$87.27M	$84.45M
Operating Income	-$62.74M	-$63.86M	-$73.62M	-$87.15M	-$84.44M
EBITDA	-$61.87M	-$62.98M	-$72.79M	-$86.34M	-$83.58M
Pretax Income	-$53.80M	-$56.60M	-$67.04M	-$81.32M	-$78.69M
Net Income	-$53.80M	-$56.60M	-$67.04M	-$81.32M	-$78.69M
Diluted EPS	-0.81	-0.85	-1.01	-1.22	-1.18
Diluted Shares	66.38M	66.39M	66.42M	66.49M	66.57M

CLDX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$17.14M	$23.04M	$36.04M	$28.87M	$35.73M
Receivables	$1.06M	$90.00K	$90.00K	$2.02M	$230.00K
Current Assets	$693.76M	$648.40M	$604.34M	$534.66M	$459.22M
Total Assets	$739.47M	$692.41M	$648.44M	$582.98M	$511.25M
Current Liabilities	$32.02M	$32.96M	$46.47M	$50.99M	$51.47M
Total Debt	$3.43M	$3.03M	$2.62M	$2.34M	$1.91M
Total Liabilities	$36.49M	$37.00M	$50.08M	$55.82M	$55.03M
Retained Earnings	-$1.61B	-$1.67B	-$1.73B	-$1.81B	-$1.89B
Shareholders' Equity	$702.98M	$655.41M	$598.36M	$527.16M	$456.23M
Working Capital	$661.74M	$615.44M	$557.87M	$483.67M	$407.75M

CLDX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$54.37M	-$44.01M	-$48.63M	-$63.94M	-$65.59M
Capital Expenditure	-$265.00K	-$728.00K	-$440.00K	-$1.28M	-$1.64M
Free Cash Flow	-$54.64M	-$44.73M	-$49.07M	-$65.22M	-$67.23M
Depreciation & Amortisation	$867.00K	$873.00K	$824.00K	$816.00K	$854.00K
Stock-Based Compensation	$9.32M	$9.19M	$8.80M	$8.91M	$8.52M
Investing Cash Flow	$42.95M	$49.85M	$60.85M	$55.42M	$72.12M
Financing Cash Flow	$202.00K	$63.00K	$774.00K	$1.35M	$327.00K
Net Change in Cash	-$11.22M	$5.91M	$12.99M	-$7.17M	$6.86M

Market Snapshot

About

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies for cancer and other difficult-to-treat diseases. Headquartered in Hampton, New Jersey, the company advances a pipeline of antibody-based therapeutics designed to engage the immune system. Key programs include barzolvolimab for chronic urticaria and mast cell-driven diseases, and CDX-0159 for inflammatory conditions. Celldex leverages its expertise in immunology to create novel treatments addressing significant unmet medical needs.